Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Combinations for cancer prevention

Combination therapies involving inhibitors of the epidermal growth factor and cyclooxygenase signaling prevent colorectal adenomas in mice. This synergistic effect may be due to the convergance of these two signaling pathways (pages 1024–1028).

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Interactions between the epidermal growth factor receptor (EGFR) and Cyclooxygenase (COX) pathways.

References

  1. Torrance, et al. Combinatorial chemoprevention of intestinal neoplasia using an NSAID and an EGFR-kinase inhibitor. Nature Med. 6, 1024 –1028 (2000).

    Article  CAS  Google Scholar 

  2. Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342 , 1946–1952 (2000).

    Article  CAS  Google Scholar 

  3. Pegram, M. et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659– 2671 (1998).

    Article  CAS  Google Scholar 

  4. Kelloff, G. et al. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev. 5, 657–666 ( 1996).

    CAS  PubMed  Google Scholar 

  5. Masferrer, J.L. et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 Inhibitors. Cancer Res. 60, 1306– 1311 (2000).

    CAS  PubMed  Google Scholar 

  6. Tsujii, M. et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93, 705–716 (1998).

    Article  CAS  Google Scholar 

  7. Williams, C.S., Tsujii, M., Reese, J., Dey, S.K. & DuBois, R.N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105, 1589–1594 (2000).

    Article  CAS  Google Scholar 

  8. He, T.C., Chan, T.A., Vogelstein, B. & Kinzler, K.W. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs . Cell 99, 335–345 (1999).

    Article  CAS  Google Scholar 

  9. Feldman, A.M., Lorell, B.H. & Reis, S.E. Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 102, 272–274 (2000).

    Article  CAS  Google Scholar 

  10. Laine, L. et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117 , 776–783 (1999).

    Article  CAS  Google Scholar 

  11. Simon, L.S. et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. J. Am. Med. Assoc. 282, 1921–1928 (1999).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gupta, R., DuBois, R. Combinations for cancer prevention. Nat Med 6, 974–975 (2000). https://doi.org/10.1038/79664

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/79664

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing